Market Cap
$6.3B
CGON
CG Oncology, Inc.
$67.38 ▼ -1.42%
Prev close $68.35Market cap$6.3B
ConsensusStrong Buy
12-mo target$91.08 (+35.2%)
▲ Bullish
Analyst conviction 9/10
Insider Buying Cluster (3 insiders)High Impact Filing (7/10)32 New Institutional Positions18 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on CGON right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (90%)
Inst. Holders
50 funds
Inst. Value
$4.2B
Inst. Activity
32 buys / 18 sells
Insider Activity
$24.8M buy / $4.1M sell
Insider Net $
$20.7M
Social Sentiment
50° Neutral
SEC Reports
14
Press Releases
3
Price chart 30d -9.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 22, 2026 short_volume
Short Volume: CGON — 74.5% short (0.4M / 0.5M)
Short: 394,698 | Exempt: 2,068 | TRF Vol: 529,949 | Short Ratio: 74.5% | Off-exchange volume (dark p
Sep 15, 2026 Insider
POST LEONARD E sold 1,000 shares
Director @ $72.98 ($73.0K)
Sep 15, 2026 Insider
POST LEONARD E acquired via exercise 1,000 shares
Director @ $0.6000 ($600.00)
Aug 14, 2026 Insider
Aug 6, 2026 SEC POST LEONARD E sold 1,000 shares
Director @ $74.54 ($74.5K)
CG Oncology reported Q2 2026 EPS of -$0.90, significantly wider than the consensus estimate of -$0.64 (a 40.6% miss), wi
PRESS-RELEASE — Impact 7/10
CG Oncology upsized its at-the-market (ATM) equity offering by $500M to a total of $1.05B, after already selling $550M i
424B5 — Impact 6/10
CG Oncology published Phase 3 BOND-003 Cohort C results for cretostimogene in BCG-unresponsive NMIBC in The Lancet Oncol
Impact 7/10
CG Oncology is the defendant in a Delaware Superior Court patent infringement case filed by ANI Pharmaceuticals. The opi
COURT-RULING — Impact 4/10
Analyst ratings buy % -5.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
90% rate it Buy or better · 21 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 7, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Aug 7, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
| Aug 7, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| May 19, 2026 | Wolfe Research | INITIATE | Peer Perform | 52% |
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 14, 2026 | Truist Securities | REITERATE | Buy | 55% |
| May 11, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| May 11, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| May 11, 2026 | Truist Securities | REITERATE | Buy | 55% |
| May 11, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 14 | 2 | 0 | 0 | 90% | |
| Aug 1, 2026 | 5 | 14 | 2 | 0 | 0 | 90% | |
| Jul 1, 2026 | 5 | 15 | 2 | 0 | 0 | 91% | |
| Jun 1, 2026 | 5 | 15 | 2 | 0 | 0 | 91% | |
| May 1, 2026 | 5 | 15 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 5 | 15 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 5 | 15 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 5 | 15 | 1 | 0 | 0 | 95% |
Price targets
Where 13 covering analysts think CGON trades over the next 12 months.
$91.08 +35.2% upside Strong Buy
Current$67.38 Low$79.00 Median$90.00 High$108.00 13 analysts
$79.00$108.00
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
14 SEC filing reports analyzed · 2 bullish, 2 bearish, 1 mixed, 9 neutral · avg impact 4.1/10.Plus 3 press releases.
BEARISHPRESS-RELEASE7/10
CG Oncology reported Q2 2026 EPS of -$0.90, significantly wider than the consensus estimate of -$0.6
Aug 6, 2026
BEARISH424B56/10
CG Oncology upsized its at-the-market (ATM) equity offering by $500M to a total of $1.05B, after alr
Aug 6, 2026
NEUTRALCOURT-RULING4/10
CG Oncology is the defendant in a Delaware Superior Court patent infringement case filed by ANI Phar
Jul 23, 2026
NEUTRALCLUSTER2/10
Two CG Oncology directors sold a combined $1.89M in stock over a 7-day window, with the bulk ($1.82M
Jul 18, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 22, 2026
short_volume
Short Volume: CGON — 74.5% short (0.4M / 0.5M)
Short: 394,698 | Exempt: 2,068 | TRF Vol: 529,949 | Short Ratio: 74.5% | Off-exchange volume (dark pool + OTC)
Sep 2, 2026
other
CG Oncology to Present at Upcoming Investor Conferences in September
DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Of
Sep 2, 2026
ftd
FTD: CGON — 129,916 shares ($9.9M) failed to deliver
Settlement: 20260902, Price: $75.86, FTD Value: $9,855,427.76, CG ONCOLOGY INC COM
Aug 19, 2026
other
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of
Aug 7, 2026
earnings_calendar
CGON Q2 2026 Earnings Scheduled — 2026-08-07
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.81 | $-0.96–$-0.66 | -42.0% | +0.7% | 0↑ 10↓ | $0.0B | 12 |
| Next Q | $-0.84 | $-1.03–$-0.67 | -64.3% | +0.3% | 0↑ 9↓ | $0.0B | 12 |
| Current FY | $-3.23 | $-3.60–$-2.79 | -55.3% | -0.8% | 0↑ 10↓ | $0.0B | 12 |
| Next FY | $-3.02 | $-3.63–$-2.15 | 6.5% | -4.0% | 2↑ 7↓ | $0.1B | 12 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.810 | — |
| 7d ago | $-0.810 | — |
| 30d ago | $-0.816 | +0.006 |
| 60d ago | $-0.667 | -0.142 |
| 90d ago | $-0.667 | -0.142 |
Institutional ownership
Which big funds own CGON (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $4.2B total value (59,234,101 shares) as of 2026-Q2. Top holders: NOMURA, RTW, BlackRock,. Net buying activity: 32 institutions added/increased vs 18 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| RTW INVESTMENTS, LP | 8,514,590 | $605.0M | 14.4% | — |
| BlackRock, Inc. | 6,256,288 | $444.5M | 10.6% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 5,324,751 | $378.3M | 9.0% | — |
| FMR LLC | 4,161,493 | $295.7M | 7.0% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3,465,197 | $246.2M | 5.9% | — |
| STATE STREET CORP | 3,437,590 | $244.2M | 5.8% | ADD +29.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,316,793 | $235.7M | 5.6% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,153,277 | $153.0M | 3.6% | ADD +34.8% |
| Caption Management, LLC | 1,779,200 | $126.4M | 3.0% | ADD +28.0% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 2,647,054 | 3,437,590 | +29.9% | $244.2M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 1,596,864 | 2,153,277 | +34.8% | $153.0M |
| MORGAN STANLEY | DOUBLED | 520,213 | 1,177,109 | +126.3% | $83.6M |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,449,364 | 984,918 | -32.0% | $70.0M |
| UBS Group AG | TRIM | 1,311,978 | 977,695 | -25.5% | $69.5M |
| GOLDMAN SACHS GROUP INC | TRIM | 1,159,239 | 857,713 | -26.0% | $60.9M |
| Jefferies Financial Group Inc. | NEW | — | 769,947 | — | $54.7M |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | TRIM | 1,064,966 | 761,807 | -28.5% | $54.1M |
| AMERICAN CENTURY COMPANIES INC | DOUBLED | 4,907 | 726,154 | +14698.3% | $51.6M |
| NORTHERN TRUST CORP | ADD | 519,669 | 677,912 | +30.5% | $48.2M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 40 transactions. Net $20.7M — $24.8M bought, $4.1M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | POST LEONARD E | Director | SELL | 1,000 | $72.98 | $73.0K |
| Sep 15, 2026 | POST LEONARD E | Director | EXERCISE | 1,000 | $0.6000 | $600.00 |
| Aug 14, 2026 | POST LEONARD E | Director | SELL | 1,000 | $74.54 | $74.5K |
| Aug 14, 2026 | POST LEONARD E | Director | EXERCISE | 1,000 | $0.6000 | $600.00 |
| Jul 15, 2026 | POST LEONARD E | Director | SELL | 1,000 | $71.17 | $71.2K |
| Jul 15, 2026 | POST LEONARD E | Director | EXERCISE | 1,000 | $0.6000 | $600.00 |
| Jul 10, 2026 | Mulay James | Director | SELL | 24,165 | $75.16 | $1.8M |
| Jul 10, 2026 | Mulay James | Director | EXERCISE | 24,165 | $26.63 | $643.5K |
| Jun 25, 2026 | Liu Brian Guan-Chyun | Director | BUY | 371,085 | $66.87 | $24.8M |
| Jun 24, 2026 | POST LEONARD E | Director | SELL | 5,000 | $70.00 | $350.0K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CGON.
Shares short
11,254,500
Settlement Sep 15, 2026
Change vs prior
-1.2%
Semi-monthly cycle
Days to cover
17.0
At avg daily volume
Of shares outstanding
≈12.7%
Estimate — not % of float
All CGON filing & press-release reports (17)
- PRESS-RELEASE reportAug 6, 2026
- 424B5 reportAug 6, 2026
- PRESS-RELEASE reportJul 27, 2026
- COURT-RULING reportJul 23, 2026
- CLUSTER reportJul 18, 2026
- 144 reportJun 25, 2026
- 144 reportJun 23, 2026
- INST-CLUSTER reportJun 12, 2026
- 8-K reportMay 26, 2026
- PRESS-RELEASE reportMay 15, 2026
- 8-K reportMay 8, 2026
- PRESS-RELEASE reportMay 8, 2026
- DEFA14A reportApr 24, 2026
- 144 reportApr 17, 2026
- 8-K reportApr 13, 2026
- INST-CLUSTER reportFeb 28, 2026
- PRESS-RELEASE reportFeb 28, 2026